Women are twice as likely as men to be diagnosed with MS and 450,000 women in Europe are affected by the condition. CRA investigated the burden of MS on women patients and the implications on Europe’s economy and society. Our research found a significant impact for women in terms of their family life, career progression and labour market role, that is not recognised by current MS polices. Our analysis suggests a need for greater awareness initiatives to drive early diagnosis and multidisciplinary treatment approaches to facilitate timely access to care. Also, social and workplace support can increase participation in the labour force and social activities, supporting women, their families and the wider economy.
MFN is rewriting the launch planning playbook: Commercial and market access strategies must integrate to succeed
MFN-related uncertainty is reshaping pharmaceutical launch planning by making pricing, sequencing, and forecasting decisions more interconnected and...